News >

Larotrectinib Update Shows Durable Responses in TRK-positive Cancers

Jason Harris
Published: Thursday, Feb 22, 2018

Dr David Hyman

David Hyman, MD
Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor published in the New England Journal of Medicine (NEJM).1

publication show the potential that larotrectinib has for patients who have TRK fusion cancers,” David Hyman, MD, senior study author and chief of the Early Drug Development service at Memorial Sloan Kettering Cancer Center, said in a statement. “These data warrant screening for TRK fusions in patients of all ages with advanced solid tumors.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication